Podcasts about Colorectal cancer

A comprehensive look at lifestyle factors and cancer rates among both older and younger people has left many people scratching their heads. The UK study examined a range of exposures and lifestyle factors trying to elucidate relationships, especially those that … What accounts for increases in colorectal cancer among younger people? Elizabeth Tracey reports Read More »

A new, comprehensive study takes a look at lifestyle factors and colorectal cancer in younger people and fails to find a relationship. Kimmel Cancer Center director William Nelson at Johns Hopkins says he thinks it may be more subtle and … Is there a relationship between diet, obesity and colorectal cancer? Elizabeth Tracey reports Read More »

Advocates demand answers after motel shelter program left residents stranded. Plus, doctors approach treatment different as more young adults are diagnosed with colorectal cancer. Finally, new podcast shares Indigenous peoples' stories.

Colorectal cancer is now the #1 cancer killer in Americans under 50 — and roughly 60% of cases are diagnosed at stage III or IV. What if your toilet could spot the earliest sign years before symptoms?Robert Lufkin MD sits down with Scott Hickle, co-founder and CEO of Throne Science, to talk about the first AI-powered smart toilet — a hands-free, daily monitor that detects fecal occult blood, tracks gut microbiome shifts, measures hydration and prostate health via sonouroflowmetry, and uses AI to coach behavior change. We unpack why your waste is the richest health signal you currently ignore, the Warren Buffett car-sensor analogy for continuous health monitoring, the 46% hemorrhoid risk from phone use on the toilet, and Throne's 10-year vision to be the first alarm system for cancer.CHAPTERS00:00 — Introduction01:14 — Meet Scott Hickle: From Mechanical Engineer to Smart Toilet CEO03:00 — How a Call With His Mom Sparked the Throne Idea05:02 — Why Your Waste Is the Richest Health Signal You Ignore07:02 — How Modern Plumbing Made Stool Analysis Taboo10:02 — Fecal Occult Blood: The Earliest Sign of Colorectal Cancer13:02 — Why Colorectal Cancer Is Now the #1 Cancer Killer Under 5014:30 — The Warren Buffett Car Sensor Analogy for Continuous Health Monitoring16:03 — Throne vs Gut Microbiome Tests: A CGM for Your Gut18:03 — Stress Is the #1 Driver of Gut Health (And Other Self-Experiments)22:04 — The 46% Hemorrhoid Risk From Phone Use on the Toilet24:04 — How the Throne Hardware and AI Software Actually Work27:00 — Sonouroflowmetry: Measuring Prostate Health From the Sound of Your Pee29:05 — Privacy, Data Security, and Camera Placement31:05 — Medical Advisors, Clinical Studies, and FDA Pathway34:06 — The AI Gut Health Coach and Behavior Change37:06 — The 10-Year Vision: A First Alarm System for Cancer40:07 — Where to Pre-Order Throne (thronescience.com)KEY TAKEAWAYSColorectal cancer is the only top-five cancer whose mortality has risen every year since 2005 — and it's now the #1 cancer killer in Americans under 50.Polyps take 7–10 years to become tumors. Colorectal cancer is one of the few cancers we know how to cure before it becomes cancer — but only 3–6% of people return the at-home FIT test.Visible blood in stool requires 40,000–50,000 µg of hemoglobin per gram. The FIT test detects 10–20 µg/g — about 8,000× more sensitive than what your eye can see.A single bleed could be a hemorrhoid or food poisoning. A monotonic four-to-six-month rising trend is the pattern that signals colorectal cancer — and you can only see patterns with continuous monitoring.Stress is the #1 driver of gut health in Scott's own n=1 self-experiments — bigger than any food, supplement, or fiber intervention he's tried.Sitting on the toilet with a phone for more than 5 minutes is associated with a 46% increased risk of hemorrhoids (Inan et al., PLOS One 2025).STUDIES & SOURCES MENTIONEDAmerican Cancer Society / JAMA, January 2026 — Cancer mortality decline under 50 — https://pressroom.cancer.org/under-50-mortality-declinesInan et al., PLOS One 2025 — Smartphone use on the toilet and hemorrhoid risk — https://pubmed.ncbi.nlm.nih.gov/40901789/Scott Hickle, TEDxBoston — "The History and Power of Poop" — https://www.youtube.com/watch?v=v42gznW6cuADr. David Rubin, MD, University of Chicago (Throne medical advisor) — ⭐ Enjoying the show? Please leave a 5-star review on Apple Podcasts — it takes 30 seconds and helps more people discover the science of health and longevity. Thank you!New episodes every Tuesday & Thursday. Subscribe so you don't miss one.Continue this conversation on Substack: https://robertlufkinmd.substack.comLies I Taught In Medical School — Free sample chapter: https://www.robertlufkinmd.com/lies/Web: https://www.robertlufkinmd.comYouTube: https://www.youtube.com/robertlufkinmdX: https://x.com/robertlufkinmdInstagram: https://www.instagram.com/robertlufkinmd/TikTok: https://www.tiktok.com/@robertlufkinLinkedIn: https://www.linkedin.com/in/robertlufkinmd/

"Radiation therapy is often extremely well tolerated in colorectal cancer. Technology has really changed things. But location of the tumor can affect side effects, such as radiation dermatitis. If a patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case," ONS member Lorraine Drapek, DNP, FNP-BC, AOCNP®, nurse practitioner in the Department of Radiation Oncology at Massachusetts General Hospital in Boston, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radiation side effects in colorectal cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by June 5, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the side effects of radiation to treat colorectal cancer. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 374: Colorectal Cancer Treatment Considerations for Nurses Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer High-Fiber Diet Reduces Diarrhea in Colorectal Cancer Survivors Hyperbaric Oxygen Therapy Shows Promise for Certain Radiation Side Effects Increasing Incidence of Colorectal Cancer in Younger Adults Is a Call to Action for Oncology Nurses Oncology Drug Reference Sheet: 5-Fluorouracil Oncology Drug Reference Sheet: Oxaliplatin Oncology Nurses Are Key in Sexual Health Conversations With Minority Women Sexual Considerations for Patients With Cancer The Intersection of Pelvic Health and Oncology Optimizes Sexual Symptom Management ONS book: Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Radiation Therapy Certificate™ ONS ROCN™ Certification Review™ Clinical Journal of Oncology Nursing articles: Sexual Dysfunction: Common Side Effect Updated Interventions for Radiation-Induced Diarrhea: Putting Evidence Into Practice With the Oncology Nursing Society Physical Activity: A Systematic Review to Inform Nurse Recommendations During Treatment for Colorectal Cancer ONS Learning Libraries: Colorectal Cancer Radiation Advanced Practitioner Society for Hematology and Oncology American Society for Radiation Oncology American Society of Clinical Oncology Clinical Practice Guidelines Colontown Colorectal Cancer Alliance To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In recent years, there has been more nonsurgical management of rectal cancer, especially in what we call the low-lying population. This is the population of patients who would likely end up with a permanent colostomy because their cancer is so low in terms of being close to or involving the anal verge. There is now a regimen where these patients can get their chemotherapy followed by their chemoradiation and then be monitored on close surveillance without surgery." TS 2:23 "Another assessment would be to assess what effects have they had from their chemotherapy that they're bringing with them. FOLFOX-based treatment is commonly used, and the platinum therapy oxaliplatin often causes peripheral neuropathy. What is the patient having? What are those symptoms like? Are they having peripheral neuropathy? If they are that is likely not going to get better or improve during their whole course of radiation. In fact, sometimes when oxaliplatin therapy stops, the peripheral neuropathy can get worse as patients are going through other treatments." TS 5:42 "If the patient has a low-lying tumor, if it's less than six centimeters from the anal verge, the patient is likely to have some skin reaction. It's good to be proactive if that's the case. And then proactively minimizing radiation dermatitis effects, such as keeping the area clean, good washing of the area, and prophylactically starting them on or having someone start them on steroid creams a couple of times a day to minimize that radiation dermatitis effect in the long run." TS 7:25 "I have a sexual health clinic for women with these effects. It's very important as nurses that if you can develop the comfort to ask patients about their sexual activity—it's hard, but it really needs to be done. And I will tell you that the healthcare providers are not doing it. They don't have time, and like us as nurses, we don't get this in school, and neither do they. The other providers don't get it in school either, but it's important. Patients are getting more and more worried about their sexual health. They're coming to us at a younger age, and this is really, really important to address." TS 15:35 "I would say that working with your advanced practice providers and education for advanced practice providers has definitely been focusing on [sexual health] more. Your PAs and your NPs—I think they're going to have the ears and the wherewithal to be able to be your allies and colleagues in this. By and large, it's my APP colleagues and nursing that I talk to the most about this. … Again, it's not an easy thing to bring forward, having dilators in place. But I will tell you in the department that I work in, it was me and couple of nurses who pushed this issue with the physicians for two years and finally got it put in place. It can be done. There's a lot more centers out there doing that." TS 21:51

ChristianaCare researchers identified a developmental genetic pattern that showed how colorectal cancer develops. The findings revealed that certain types of genes drive cancer growth and resistance, and how the precise timing of how they develop is linked to colon cancer formation.The research team's work also showed the genes can predict survival in colorectal cancer patients, indicating it can be a marker of disease behavior and a target for future therapies.This week, Delaware Public Media's Joe Irizarry sat down with Bruce Boman, M.D., senior author of the study and senior researcher at ChristianaCare's Helen F. Graham Cancer Center & Research Institute to discuss this colorectal cancer research.

BUFFALO, NY – June 2, 2026 – A new #research paper was #published in Volume 17 of Oncotarget on May 20, 2026, titled “Microenvironmental CTHRC1 has a pro-tumorigenic role in colorectal cancer.” The study was led by first author Haylee Duval from the Center for Molecular Medicine at the MaineHealth Institute for Research and the Graduate School of Biomedical Science and Engineering at the University of Maine. The study's corresponding authors were Sergey Ryzhov, Volkhard Lindner, and Michaela R. Reagan, who are affiliated with the Center for Molecular Medicine at the MaineHealth Institute for Research, the Graduate School of Biomedical Science and Engineering at the University of Maine, and Tufts University School of Medicine. Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide. While much research has focused on cancer cells themselves, growing evidence suggests that the tumor microenvironment—the network of surrounding stromal cells, immune cells, and extracellular components—plays a critical role in determining how tumors grow and spread. In this study, researchers investigated collagen triple helix repeat containing 1 (CTHRC1), a secreted protein previously associated with poor outcomes in several cancer types. Although CTHRC1 is frequently detected in tumor-associated stroma, its precise role within the colorectal cancer microenvironment has remained unclear. To address this question, the team used a genetically engineered mouse model lacking CTHRC1 and compared tumor development with that of normal mice after colorectal cancer cells were introduced. The results consistently showed that the absence of host-derived CTHRC1 significantly reduced tumor growth. Across three independent experimental cohorts, mice lacking CTHRC1 developed substantially smaller tumors than their normal counterparts. In addition, survival improved markedly. The median survival of mice with normal CTHRC1 expression was 28 days after tumor inoculation, compared with 69 days in CTHRC1-deficient mice. The researchers also found evidence that CTHRC1 influences anti-tumor immunity. Mice lacking CTHRC1 had higher percentages of CD3-positive T cells in both tumors and spleens, suggesting a more active immune response against cancer. At the same time, they exhibited reduced levels of certain myeloid immune cells associated with immune suppression. Importantly, the investigators confirmed that the colorectal cancer cells themselves did not produce detectable CTHRC1. Instead, the protein was found primarily in fibroblasts and other stromal components surrounding the tumor. This finding indicates that the tumor-promoting effects originated from the tumor microenvironment rather than from the cancer cells directly. Histological analyses further revealed striking differences in tumor structure. Tumors from CTHRC1-deficient mice contained fewer cells and showed evidence of regression, while tumors in normal mice remained densely cellular and continued to expand. Full press release - https://www.oncotarget.com/news/pr/protein-in-tumor-microenvironment-found-to-promote-colorectal-cancer-growth-and-immune-evasion/ DOI - https://doi.org/10.18632/oncotarget.28878 Correspondence to: Sergey Ryzhov - Sergey.Ryzhov@mainehealth.org; Volkhard Lindner- Volkhard.Lindner@mainehealth.org; Michaela R. Reagan - Michaela.Reagan@mainehealth.org Abstract video - https://www.youtube.com/watch?v=gTbYy6vGd7E To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

The American Cancer Society (ACS) recently updated its colorectal cancer screening recommendations, adding new stool-based and blood-based screening options. What's changed in the new American Cancer Society screening recommendations • New stool DNA and stool RNA screening tests • The role of blood-based cancer screening tests • Why colonoscopy remains the gold standard • Why a follow-up colonoscopy is still needed after a positive screening test • Screening recommendations for adults ages 45–75 • The rise in colorectal cancer among younger adults and what patients should know The most important takeaway? Colorectal cancer is highly preventable, and the best screening test is the one that gets completed. This episode is intended for educational purposes only and should not replace medical advice from your healthcare provider.  

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 1: Recent Advances in the Management of Metastatic CRC (mCRC) — Anwaar Saeed, MD CME information and select publications

Proceedings from a webinar on April 16, 2026, moderated by Dr Neil Love, including the following topics: Introduction: Research To Practice Paper of the Year! (0:00) Checkpoint Inhibitors for Localized Microsatellite Instability-High Tumors (11:12) Circulating Tumor DNA Assays (21:58) Checkpoint Inhibitors for Metastatic Disease (38:32) CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Colorectal Cancer | Faculty Presentation 2: Optimizing the Care of Patients with Nonmetastatic Colorectal Cancer (CRC) — Arvind Dasari, MD, MS CME information and select publications

New details are emerging about the negotiations to end the US-Iran war. The race for an open Senate seat in Texas is heating up just hours after a GOP primary run-off. Rescuers say they've found five of seven people trapped in a cave in Laos. We tell you why the Minneapolis police chief, a central figure in several major shootings in the city, has resigned.  Plus, the American Cancer Society is expanding its colorectal cancer screening guidelines. Learn more about your ad choices. Visit podcastchoices.com/adchoices

There's SO much information about wellness hacks, it's hard to know what's worth trying. And then there are pharmaceuticals like GLP-1 medications that seem like the magic bullet for metabolic health. With all of these, are we setting ourselves up for the next public health crisis? Before you or someone you love considers a pharmaceutical or biohack, listen to this episode. Jenn Trepeck of Salad with a Side of Fries breaks down why the wellness industry deserves more credit than mainstream media gives it, and why pharmaceutical solutions like GLP-1 medications and statins cannot carry the full weight of America's health crisis. From affordable, healthy eating strategies to the alarming long-term risks of overreliance on a single hormone pathway, Jenn makes a compelling, research-backed case for a more comprehensive approach to metabolic health. What You Will Learn in This Episode:✅ Why GLP-1 medications may be following the same trajectory as statin drugs, and what that historical pattern reveals about where we are headed with metabolic health and long-term outcomes.✅ How eating in season and shopping at ethnic grocery stores can make whole foods nutrition genuinely affordable, healthy eating for more people, regardless of income level.✅ The critical connection between reduced food intake on GLP-1 medications, nutrient deficiency, and the alarming rise of osteoporosis and cancer risk, especially for younger populations and children.✅ Why fat cell memory and the Minnesota Starvation Experiment both reveal that weight loss without lifestyle medicine and nutritional education is unlikely to produce lasting results.The Salad With a Side of Fries podcast, hosted by Jenn Trepeck, explores real-life wellness and weight-loss topics, debunking myths, misinformation, and flawed science surrounding nutrition and the food industry. Let's dive into real-life wellness and weight loss, including drinking, eating out, and skipping the grocery store.TIMESTAMPS: 00:00 Why mainstream media voices unfairly dismiss the wellness industry05:50 A critique of how major journalists cover GLP-1 medications without consulting balanced sources or opposing viewpoints13:33 The argument that pharmaceutical solutions have become the default answer instead of addressing the root causes of metabolic health issues22:29 Discussion of income, access, and why processed foods are cheaper than whole foods nutrition is a structural public health failure30:37 Practical tips for affordable healthy eating, including seasonal eating and shopping at ethnic grocery stores for better quality produce34:39 The GLP-1 conversation begins in earnest, with Jenn explaining why she calls them our generation's statin drug37:02 A deep dive into statin drug statistics, heart disease rates, and why more prescriptions have not produced better cardiovascular health outcomes41:14 Jenn outlines her predictions, including rising osteoporosis risk, bone density loss, and increased colorectal cancer risk tied to low fiber intake44:31 The role of fat cell memory, the Minnesota Starvation Experiment, and why GLP-1 medications without lifestyle medicine will not produce lasting changeKEY TAKEAWAYS:

In this JCO PO Article Insights episode, host Jordan Goldstein summarizes the article, "EXONERATE-TRaCE: A Liquid Biopsy for Tracking Response to Anti–Epidermal Growth Factor Receptor–Based Therapy in Metastatic Colorectal Cancer" byTakahashi,  et al. LINK TO FULL TRANSCRIPT

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries continues to evolve with significant scientific advancements, regulatory breakthroughs, and strategic maneuvers that are reshaping drug development and patient care. One of the noteworthy developments is the U.S. FDA's recent approval of Gilead Sciences' Hepcludex (bulevirtide) for hepatitis D. This approval marks a comeback for Gilead after previous setbacks due to manufacturing and delivery issues, highlighting the critical importance of addressing regulatory feedback. It's a testament to persistence in overcoming manufacturing challenges to ensure vital therapies reach those in need. This approval signifies a milestone as it's the first FDA-approved therapy targeting chronic hepatitis D virus infection—a niche condition with limited treatment options. Similarly, Pfizer's Braftovi (encorafenib) is expanding its global reach beyond U.S. borders with regulatory approvals in the EU and Canada for colorectal cancer treatment. This broadening geographic footprint reflects a broader industry trend where companies aim to maximize the therapeutic impact of oncology drugs across diverse patient populations. Meanwhile, Astellas Pharma is navigating the looming patent cliff for its prostate cancer drug Xtandi by actively pursuing new licensing deals and implementing cost-cutting measures. This dual approach underscores a widespread industry strategy where companies balance acquisitions with operational efficiency to sustain growth. In the radiopharmaceutical sector, there's notable activity with Lantheus Holdings possibly being acquired by Curium for $7 billion. This potential deal underscores growing interest in radiopharmaceuticals due to their precision in targeting specific cancer types. Complementing this is Niowave's $75 million investment in a radiopharmaceutical isotope plant in Michigan, set to produce actinium-225 by 2028—an isotope crucial for targeted cancer therapies. Regulatory landscapes are also in flux with continued reforms at the FDA despite leadership changes. Initiatives like the Commissioner's National Priority Voucher program illustrate regulatory bodies' commitment to streamlining drug approvals and fostering innovation. On an international note, SK Bioscience is partnering with Colombia to locally produce the chickenpox vaccine Skyvaricella, enhancing vaccine accessibility through technology transfer. Similarly, Eli Lilly's acquisition spree in infectious disease research signals a robust push toward expanding its R&D pipeline for viral and bacterial pathogens. Eli Lilly has announced plans to acquire Curevo, Limmatech Biologics, and another vaccine company for up to $3.8 billion. This strategic acquisition underscores a commitment to enhancing capabilities in infectious diseases—a field that has gained focus post-COVID-19 pandemic. By integrating these companies, Eli Lilly aims to leverage their platforms and expertise for advanced therapeutic solutions against infectious diseases. In gene editing, Eli Lilly is preparing for a Phase 2 trial of a lipid-lowering gene editor from Verve Therapeutics, showing promising cholesterol reductions akin to PCSK9 inhibitors. This highlights gene editing's potential in addressing cardiovascular diseases. A significant development from Lilly's pipeline includes promising results from their base editor technology acquired through Verve Therapeutics—an exciting breakthrough suggesting substantial potential for gene-editing technologies addressing genetic disorders like high cholesterol. In oncology, AstraZeneca and Daiichi Sankyo's Datroway gained FDA approval for triple-negative breast cancer as a first-line treatment. This antibody-drug conjugate targets Trop2, demonstrating the potential of targeted therapy in difficult-to-treat cancers. Kura Oncology's combination therapy featuring darlifarnib and Krazati showed up to a 69% response rate in KRAS G12C-mutated solid tumors during Phase 1 trials, emphasizing precision medicine's potential in targeting specific genetic mutations driving cancer progression. In obesity management, Eli Lilly's retatrutide achieved Phase 3 success with bariatric surgery-like outcomes. The drug acts as a triple hormone receptor agonist, showcasing advancements in metabolic therapies targeting obesity—a condition linked with numerous comorbidities. Moderna's mFlusiva is poised for an FDA advisory committee review as an influenza preventative for older adults—an extension of Moderna's mRNA technology initially used against COVID-19. Collectively, these developments highlight an industry leveraging cutting-edge science and technology to tackle complex medical challenges. As pharmaceutical giants like Eli Lilly consolidate their positions through acquisitions and research collaborations, transformative advancements promise to reshape patient care across various therapeutic areas. These initiatives not only reflect the industry's dynamic nature but also its pivotal role in addressing unmet medical needs worldwide. Eli Lilly's recent strategic acquisitions underscore its commitment to advancing pharmaceutical innovations, particularly in vaccines and cholesterol management sectors. Acquiring three vaccine-focused biotech firms signifies substantial investment in expanding its vaccine portfolio—a move aligned with global immunization strategies. This follows hiring Peter Marks from the FDA, indicating a strategic focus on bolstering expertise within the vaccine domain. The company has been recognized by IDEA Pharma as a leader in pharmaceutical innovation—a testament to its robust pipeline and successful integration of scientific advancements into marketable therapies. Across oncology landscapes highlighted at ASCO conferences are exciting potentials like Summit Therapeutics and Akeso's potential Keytruda rivals that could reshape cancer treatment paradigms if proven effective. As pharmaceutical landscapes continue evolving rapidly through scientific strides tempered by regulatory hurdles—the current environment promises significant advancements offering new hope while demanding strategic agility within healthcare sectors globally.Support the show

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

Dr. Jeanine Cook-Garard learns about Colorectal Cancer, because a new study by the American Cancer Society shows that -- while overall cancer deaths in people younger than 50 in the United States has decreased since their last study -- only colorectal cancer mortality has increased, advancing it from the fifth most common cause of cancer death in the early 1990s to the first in 2023, seven years earlier than predicted. She speaks with Dr. Pascale M. White, a Fellow of the American College of Gastroenterology, and Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai.

Marwan Fakih, MD - Making a Difference in Refractory Metastatic Colorectal Cancer: Practical Strategies to Positively Impact the Patient Journey Across Practice Settings

In this episode of Health Confidential, host Simone Gisondi explores the powerful connection between emotional healing, spiritual awakening, nervous system regulation, and physical recovery through the extraordinary healing journey of Malka Shivdasani. This conversation dives into holistic healing, mind-body medicine, trauma release, meditation, and the emotional roots of chronic illness and cancer.After years of living as a people-pleasing wife, mother, and business owner, Malka experienced a major spiritual awakening following her son's devastating spinal cord injury in 2006. Searching for healing beyond conventional medicine, she immersed herself in meditation, emotional healing, subconscious reprogramming, and the teachings of renowned spiritual teachers including Joe Dispenza, Wayne Dyer, Louise Hay, and Bruce Lipton. Years later, in 2024, Malka was diagnosed with stage 3 colorectal cancer, including lymph node involvement and a rectal tumor. Rather than pursuing chemotherapy, radiation, and surgery, she chose a deeply integrative path focused on meditation, hypnotherapy, trauma healing, emotional release, energetic healing, nervous system healing, and holistic medical support. Through deep inner transformation and unwavering trust in the body's innate intelligence, Malka eventually received scans showing no visible cancer.Together, Simone and Malka discuss colon cancer healing, emotional trauma, spiritual healing, self-love, subconscious beliefs, and how chronic stress and self-abandonment can impact long-term health. This episode is a powerful exploration of holistic cancer recovery, personal transformation, and reclaiming the body's ability to heal.KEY TAKEAWAYS• Chronic people-pleasing and self-abandonment can contribute to emotional and physical imbalance.• Trauma and unresolved emotions may remain stored in the nervous system and body.• Meditation, subconscious healing, and spiritual practices can support emotional transformation.• Healing often requires addressing emotional, energetic, mental, and physical health together.• Listening to intuition and inner alignment can play a powerful role in personal healing journeys.BEST MOMENTS• “There's this wisdom, and it's so beautiful inside that what we carry, the power that we carry.”• “Of course nothing worked, and then we started going inward, of course the way out is in.”• “So, as we were healing, we were healing the community.”• “It was feeding the fear and doing it anyway, because I knew I did not want to do chemo.”• “These thoughts are just coming in to be released. It's all about a healing process.”GUEST INFORMATIONMalka ShivdasaniSoul alignment coach, meditation teacher, and founder of Infinite Love meditation center helping individuals reconnect with their inner healing power through meditation, emotional healing, trauma release, and spiritual transformation.Instagram: malkasshivHOST BIOSimone Gisondi is a coach, published author, and host of Health Confidential, dedicated to exploring root-cause healing through nutrition, mindset, emotional wellness, and holistic health practices.#ColonCancer #ColonCancerHealing #Stage3ColonCancer #CancerRecovery #HolisticHealing #MindBodyHealing #MeditationHealing #TraumaHealing #EmotionalHealing #SpiritualHealing #IntegrativeMedicine #NervousSystemHealing #SubconsciousHealing #AlternativeHealing #HolisticHealth #WellnessPodcast #HealthPodcast #CancerJourney #SelfHealing #JoeDispenzaSimone is a Holistic Health Practitioner and researcher exploring the deeper biological, emotional, and environmental roots of disease.On this podcast, she examines how health, trauma, consciousness, lifestyle, and biology interesect and how the instructions we give the body through food, environment, belief, and emotional regulation shape our health outcomes.Her work focuses on helping individuals understand the real drivers of illness and reclaim their health through customized lifestyle, nutritional, and mindset changes.If you're navigating a health challenge and would like personalized guidance, Simone offers a limited number of private consultations. By appointment only.Inquire about working with her here: https://www.simonegisondi.com/book-online Visit her website: https://www.simonegisondi.com/Follow Simone: https://www.instagram.com/simone.gisondi/Subscribe and leave a review. Hosted on Acast. See acast.com/privacy for more information.

Canadians under 50 are twice as likely as prior generations to get colorectal cancer. In this encore episode, we met up with battle rapper Bishop Brigante, whose delayed Stage 4 colorectal cancer diagnosis drove him to advocate for better access to colonoscopies.

View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter's Weekly Newsletter In this episode, Peter takes a deep dive into colorectal cancer (CRC) screening, explaining why it is one of the most preventable cancers and why getting screening right can have life-saving implications. He walks through how colorectal cancer develops and why it is uniquely well-suited to early detection and prevention, with a particular emphasis on the dual role of colonoscopy as both a diagnostic and therapeutic tool. Peter also examines the concerning rise in early-onset CRC among younger adults, highlighting why awareness and timely screening matter more than ever. The episode provides a practical guide to preparing for and evaluating the quality of a colonoscopy, including how to think about appropriate screening intervals and the real risks and tradeoffs involved. Finally, Peter explores the expanding landscape of non-invasive screening options, offering clear insight into what these alternatives can and cannot do so listeners can make informed decisions about their care at any age. We discuss: CRC statistics and goals for this episode [1:00]; Colorectal cancer development: polyp progression, risk types, and the window for prevention [4:00]; Why colorectal cancer is uniquely screenable: direct visualization and the dual role of colonoscopy [6:30]; Colonoscopy effectiveness: prevention through polyp removal and interpreting the NordICC trial data [8:15]; Rising colorectal cancer in younger adults: trends, possible causes, and the case for earlier screening [12:15]; Colonoscopy preparation: why bowel prep matters and how newer options improve the experience [16:45]; Colonoscopy quality, polyp miss rates, and personalized screening intervals [20:00]; Colonoscopy risks versus colorectal cancer risk: understanding the true risk-benefit tradeoff [29:30]; Non-invasive screening options for CRC: benefits, limitations, and their role alongside colonoscopy [37:00]; Colorectal cancer prevention principles: why screening matters and the role of colonoscopy [39:30]; and More. Connect With Peter on Twitter, Instagram, Facebook and YouTube

Colorectal cancer is making headlines — and increasingly, it's affecting younger adults. Stephen Kucera, MD, Medical Director of Gastroenterology and Endoscopic Oncology, explains why diagnoses are rising in people under 55, what may be driving the trend, and the warning signs no one should ignore. He also shares the lifesaving steps everyone can take to reduce their risk, including when to get screened and how early detection can make all the difference. You can also watch the video recording on our Vimeo channel here. For more health tips & news you can use from experts you trust, sign up for Sarasota Memorial's monthly digital newsletter, Healthe-Matters.

Could neoadjuvant immunotherapy be considered part of the standard of care for patients with mismatch repair deficient (dMMR) colon cancer? Credit available for this activity expires: 5/1/27 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/practical-community-colorectal-cancer-clinic-aligning-2026a1000dw7?ecd=bdc_podcast_libsyn_mscpedu

Speakers:Mital Patel, MD, Director of Hematology and Medical Oncology, Dignity Health Cancer Institute at St. Joseph's Hospital and Medical CenterRonald Gagliano, MD, System Vice President, Oncology Service Line, Physician Executive and Chairman, Department of Surgery, Dignity Health Medical Group ArizonaModeratorAnkita Sagar, MD, MPH, FACP, FAMWA, System Vice President, Clinical Transformation and Well-Being

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer. CME information and select publications here.

Good therapeutic options for metastatic colorectal cancer are limited after the fluoropyrimidine-based options are exhausted. This week, we explore the role of trifluridine-tipiracil (Lonsurf) and bevacizumab (VEGF inhibitor), and a newish kid on the block, fruquitinib, an oral tyrosine kinase inhibitor and vascular endothelial growth factor receptor. While not perfect, they do represent later-line options for patientsStudies discussed in this episode:SUNLIGHTFRESCO-2 For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Role of circulating tumor DNA (ctDNA) testing in the escalation of treatment for Stage II and deescalation for Stage III colon cancer (0:00) Impact of timing on the clinical relevance of ctDNA minimal residual disease test results in localized colorectal cancer (8:58) Approach to managing Stage III colon cancer with ctDNA-positive results after adjuvant treatment (13:35) CME information and select publications

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about a new study shows the health benefits and health risks of an afternoon nap, rectal cancer rates rising for people in their 30’s and 40’s, and why he wouldn’t solely rely on a blood test to check […]

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about a new study shows the health benefits and health risks of an afternoon nap, rectal cancer rates rising for people in their 30’s and 40’s, and why he wouldn’t solely rely on a blood test to check […]

Cutting fiber may offer temporary relief—but it harms gut health long-term. Here's why the carnivore diet is a dangerous illusion. #CarnivoreMyth #FiberMatters #GutHealth #HealthTalks

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Catherine Gratz Griffin Lake Forest Hospital, joins John Williams to talk about a new study shows the health benefits and health risks of an afternoon nap, rectal cancer rates rising for people in their 30’s and 40’s, and why he wouldn’t solely rely on a blood test to check […]

Welcome to the third episode of our three-part series on colorectal cancer! In this episode of the Oncology Brothers we are joined by Dr. Rona Yaeger, a medical oncologist from the Memorial Sloan Kettering Cancer Center. Together, we dived into the management of common side effects associated with systemic treatments for colorectal cancer. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Episode Highlights: • Overview of 5-FU and capecitabine, including the importance of DPYD mutation testing and side effects like cytopenia, mucositis, and cardiac toxicity. • Discussion on the use of 5-FU bolus in both metastatic and adjuvant settings. • Insights into managing oxaliplatin-induced neuropathy and the potential benefits of oral cryotherapy. • Clinical pearls for irinotecan, including the management of diarrhea and cholinergic effects. • Considerations for using Bevacizumab, including risks of hypertension, proteinuria, and blood clots. • Tips for managing side effects of anti-EGFR agents like Cetuximab and Panitumumab, including rash and infusion reactions. • An overview of oral agents such as encorafenib, TAS-102, and Regorafenib, with a focus on dosing strategies and side effect management. Join us as we explore these critical topics and provide valuable insights for healthcare professionals managing colorectal cancer treatments. Don't forget to subscribe for more episodes! #ColorectalCancer, #SideEffectManagement, #DPYDtesting, #ChemotherapyToxicity, #SupportiveCare

There are some people you meet in life who just feel different. Ro is one of them. She came into Adam's life in 2021, and it's no surprise she was the one who had his heart. She's truly one of a kind. Someone special, funny, strong AF… and someone who shows up in a way that changes the people around her. This conversation is about them. How they met, the fun they had, the concerts, the trips and the random moments that made it all feel so easy. It's also about who she is. And why we all love her. We learned a lot from Ro. We still do. And we're all better because of her.  

Welcome back to the Oncology Brothers podcast! In this second episode of our three-part series on colorectal cancer, we dived deep into the BRAF V600E mutation and its implications for metastatic colorectal cancer treatment. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/ Join us as we discussed: The prevalence and outcomes associated with BRAF V600E mutations Recent advances in treatment options, including the BREAKWATER study The significance of biomarker testing and how it influences treatment decisions The new standard of care combining Encorafenib and Cetuximab with chemotherapy Management of overlapping side effects from targeted therapies Strategies for sequencing treatments in patients with MSI-high disease This episode is packed with valuable information for healthcare professionals and anyone interested in the latest advancements in colorectal cancer treatment. Don't miss out on the critical insights shared by our expert guest! Be sure to check out Part 1 of our series for an overview of the colorectal cancer treatment landscape, and stay tuned for Part 3, where we will focus on toxicity management and practical clinical pearls. Subscribe to our channel for more oncology insights and updates! This discussion was in support of an independent educational grant provided by Pfizer

In this episode of the Oncology Brothers podcast, we kicked off a three-part series on colorectal cancer, starting with the current treatment algorithm. They are joined by Dr. Smitha Krishnamurthi, a GI medical oncologist from the Cleveland Clinic, who walks through the evolving standard of care from early-stage disease all the way to refractory metastatic settings. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966 Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Key topics discussed included: • The evolving role of ctDNA as both a prognostic and predictive tool in stage two and three colon cancer, including its utility in oligometastatic disease surveillance. • Neoadjuvant versus adjuvant immunotherapy in MSI-high resectable colon cancer, comparing the NICHE-2 and ATOMIC trial approaches and when to use each. • Single-agent versus dual checkpoint inhibition with Nivo-Ipi for MSI-high metastatic disease, based on CHECKMATE-8HW data showing a PFS hazard ratio of 0.21. • Sequencing strategies in RAS-mutant and RAS wild-type metastatic colorectal cancer, including the role of sidedness, anti-EGFR therapy, and refractory options like fruquintinib, TAS-102, and regorafenib. Join us for this comprehensive discussion on colorectal cancer management in 2026. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology! #ColorectalCancer, #MSIHigh, #BRAFV600E, #ctDNA, #GIOncology, #OncologyBrothers

*JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]*Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2 *HEALTH AUTONOMY [COURSE]*Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy*JOIN THE COMMUNITY*Join my Community [It's Free!]: https://bit.ly/PhysionicCommunity2*EMAIL LIST*1-2 Weekly Email of Value [It's Free!]: http://bit.ly/2AXIzK6*HIRE ME FOR CONSULTING:*Consulting: https://bit.ly/3dmUl2H 0:00 - Introduction4:43 - Berberine on Colorectal Cancer21:36 - 5 Free Health Tests1:03:15 - Glycine Restriction and Cancer1:39:12 - Favorite Anti-Aging Hack2:06:00 - Lithium on Alzheimer's Disease2:29:20 - Vitamin K on Cardiovascular Disease3:14:00 - Housekeeping/Hanging Out

Featuring perspectives from Dr Stacey A Cohen, Dr Christopher Lieu and Dr Jenny Seligmann, moderated by Dr Lieu, including the following topics: Adjuvant treatment planning for Stage II or III microsatellite instability-high colon cancer (0:00) Roles of circulating tumor DNA (ctDNA), POLE mutations and advanced age in adjuvant treatment planning (6:08) Role of ctDNA in adjuvant treatment planning for Stage III colon cancer (12:31) CME information and select publications

Drs. Pedro Barata, Yi Song, Meenakshi Jeeva, and Lauren Park discuss liver-directed therapies in colorectal cancer, ongoing developments in locoregional therapies for unresectable colorectal liver metastasis, and exciting research on expanding the role of thermal ablation in liver-dominant metastatic CRC. LINK TO FULL TRANSCRIPT

Dr Stacey A Cohen from Fred Hutchinson Cancer Center in Seattle, Washington, Dr Jenny Seligmann from the University of Leeds in the United Kingdom and Dr Christopher Lieu from the University of Colorado Cancer Center in Aurora review clinical findings from the 2026 ASCO Gastrointestinal Cancers Symposium relevant to the management of localized colorectal cancer.CME information and select publications here.

Send us Fan MailCan what you eat influence your risk of colorectal cancer?In this episode of Causes or Cures, Dr. Eeks speaks with Dr. Fred Tabung, PhD, MSPH, a researcher studying diet, metabolism, and cancer prevention, about how certain dietary patterns may reduce colorectal cancer risk.Drawing on data from nearly one million people across the United States and Europe, Dr. Tabung explains how low insulinemic and anti-inflammatory diets are linked to lower colorectal cancer risk, and what this means for real-world prevention.We explore how insulin and inflammation may influence cancer pathways, how diet connects to obesity and Type 2 diabetes, and how those conditions are linked to cancer. We also discuss why early onset colorectal cancer is increasing in younger adults.The conversation also covers childhood and early life exposures, the microbiome, and what a population level approach to diet and cancer prevention could realistically look like.What we cover What low insulinemic and anti-inflammatory diets actually mean  Foods associated with lower colorectal cancer risk  How insulin and inflammation may influence cancer development  The link between diet, obesity, Type 2 diabetes, and cancer  Why early onset colorectal cancer may be increasing  What a population level nutrition strategy for cancer prevention might look likeDr. Fred Tabung is an Associate Professor of Internal Medicine at The Ohio State University and a researcher at the Ohio State University Comprehensive Cancer Center – James, where he leads the Diet, Metabolism, and Cancer Prevention Outcomes Lab. His work focuses on how dietary patterns influence cancer risk and progression, particularly through pathways related to inflammation and insulin. Using large-scale population studies and clinical research, he aims to identify practical, evidence-based dietary strategies for cancer prevention and improved outcomes across the cancer continuum.  Work with me? Perhaps we are a good match. Keep Causes or Cures Ad-Free with Listener SupportYou can contact Dr. Eeks at bloomingwellness.com.Follow Eeks on Instagram here.Follow Public Health is WeirdOr Facebook here.On Youtube.Or TikTok.SUBSCRIBE to her Newsletter here! (the bits not posted on socia media)Support the show

When Shannon Ivey was diagnosed with late-stage colorectal cancer at 42, she was a single mom in a new city with no built-in support system. What followed wasn't just a medical battle. It was a crash course in self-advocacy, resilience, and learning how to navigate a system that wasn't designed for someone in her position. In this episode, Shannon shares what it really looks like to face a life-threatening diagnosis while holding everything else together. From recognizing the symptoms she almost dismissed, to building her own medical team, to making the decision to fight when she wasn't sure she wanted to, this conversation goes beyond survival. It's about reclaiming your voice in moments when it matters most. This is a powerful reminder that even in the most overwhelming situations, you have more agency than you think. Guest Bio Shannon Ivey, MFA, AEA, PCC, is a writer, patient advocate, and International Coaching Federation–certified professional coach. She is the author of Welcome to the Sht Show: A Memoir of Colorectal Cancer and the Power of Self-Advocacy* (University of South Carolina Press, 2026), a bold and honest exploration of navigating medical crisis, identity, and personal agency. After more than 20 years in theatre as a professor, actor, and director, Shannon shifted her work toward storytelling, narrative medicine, and advocacy. Following her diagnosis with late-stage colorectal cancer at 42, she became a leader in Colontown, one of the largest online support communities for colorectal cancer patients. Her work now focuses on medical self-advocacy, health equity, and the power of storytelling to drive personal and systemic change. She is currently pursuing a PhD focused on creativity and hope in post-crisis contexts.   You'll hear About The early signs of colorectal cancer that are often overlooked Why assumptions about "normal" symptoms can be dangerous What it means to truly advocate for yourself in a medical system How to build the right team around you and make hard decisions The mindset shift that helped Shannon choose to fight Chapters 00:00 Welcome and Episode Introduction 02:00 Life Before Diagnosis and Early Warning Signs 05:00 The Moment Everything Changed 09:30 Navigating Diagnosis as a Single Parent 13:00 Making the Decision to Fight 16:30 Missed Symptoms and Medical Blind Spots 20:00 Why People Avoid Getting Checked 24:00 Breaking Stigma Around Colorectal Cancer 27:30 Building a Medical Team That Works for You 31:00 The Power of Self-Advocacy 34:30 Learning From Others and Finding Support 37:00 Life After Diagnosis and New Purpose 40:00 Shannon's Book and Message 42:30 Final Reflections and Takeaways Chuck's Challenge This week, take ownership of one area of your life where you've been waiting for someone else to take the lead. Ask questions. Speak up. Advocate for what you need. Even a small step toward self-advocacy can create a powerful shift. Connect with Shannon Instagram: https://www.instagram.com/yesitsshannonivey LinkedIn: https://www.linkedin.com/in/shannon-ivey-mfa-aea-pcc/ Facebook: https://www.facebook.com/shannonmivey Connect with Chuck Check out the website: https://www.thecompassionateconnection.com/ LinkedIn: https://www.linkedin.com/in/chuck-thuss-a9aa044/ Follow on Instagram: @warriorsunmasked Join the Warriors Unmasked community by subscribing to the show. Together, we're breaking stigmas and shining a light on mental health, one story at a time.

If you're under 50, it's likely that colorectal cancer isn't on your radar, but it should be. Once considered an older-age disease, rates are skyrocketing among young adults. Deema Zein spoke with two people diagnosed at an early age, and discussed the rise with Dr. Robin Mendelsohn, a gastroenterologist and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancers. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

If you're under 50, it's likely that colorectal cancer isn't on your radar, but it should be. Once considered an older-age disease, rates are skyrocketing among young adults. Deema Zein spoke with two people diagnosed at an early age, and discussed the rise with Dr. Robin Mendelsohn, a gastroenterologist and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancers. PBS News is supported by - https://www.pbs.org/newshour/about/funders. Hosted on Acast. See acast.com/privacy

In this special live episode recorded during Colorectal Cancer Awareness Month, she sits down with Kevin Conroy, CEO of Exact Sciences and the force behind Cologuard; Judy Faulkner, founder and CEO of Epic Systems; and epidemiologist Dr. Caitlin Murphy to dig into why this disease keeps striking younger people. They cover the leading theories like ultra-processed foods, microplastics, the microbiome and debate whether the screening age should drop below 45, and get into the symptoms doctors too often brush off. If you know someone in their 30s or 40s, send them this one. It could save a life.See omnystudio.com/listener for privacy information.

Cases of colorectal cancer in young people have risen nearly 60 percent since the early 2000s. That's according to data from the Centers for Disease Control and the National Cancer Institute. And a new study out this month by the American Cancer Society found that colorectal cancer is now the deadliest kind for those younger than 50.But this rise isn't being felt across all generations in the same way. People born around 1990 are four times more likely to develop rectal cancer than those born around 1950. And for those 65 and older, colorectal cancer rates have actually decreased.So, what's going on? And what can you do to protect yourself and your gut health? For those answers and more, we turn to a panel of experts.Find more of our programs online. Listen to 1A sponsor-free by signing up for 1A+ at plus.npr.org/the1a.To manage podcast ad preferences, review the links below:See pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

With the increasing incidence of colorectal cancer in those less than 50 years of age, one must wonder how many patients present with a Stage IV diagnosis. Take a deep dive with us discussing the management of metastatic colorectal cancer by joining our team and guests, Drs. Cathy Eng, Michael D'Angelica, and Nina Sanford.Hosts: - Dr. Janet Alvarez - General Surgery Resident at New York Medical College/Metropolitan Hospital Center- Dr. Wini Zambare – General Surgery Resident at Weill Cornell Medical Center/New York Presbyterian- Dr. Philip Bauer, Assistant Professor of Surgery, Division of Colon and Rectal Surgery, The Ohio State University Wexner Medical Center, Arthur G. James Cancer Hospital-  Dr. J. Joshua Smith MD, PhD, Chair, Department of Colon and Rectal Surgery at MD Anderson Cancer Center Guest Speakers:- Dr. Michael D'Angelica MD, FACS – Hepatopancreatobiliary Surgery, Memorial Sloan Kettering Cancer Center, Enid A. Haupt Chair in Surgery, Vice Chair, Education- Dr. Cathy Eng MD, FACP - Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, David H. Johnson Endowed Chair in Surgical and Medical Oncology, Professor of Medicine, Hematology and Oncology, VICC Associate Director for Strategic Relations and Research Partnerships, Executive Director, Young Adult Cancers Program - Dr. Nina Sanford, MD – Radiation Oncology, UT Southwestern Medical Center, Chief of Gastrointestinal Radiation Oncology Service, Associate Professor Learning Objectives:1.     Review the epidemiology, prognosis, and common metastatic patterns of metastatic colorectal cancer (mCRC).2.     Discuss the role of systemic chemotherapy and targeted therapies in the first- and subsequent-line treatment of mCRC, including the impact of molecular biomarkers such as MSI/MMR, RAS, BRAF, and HER2.3.     Evaluate the indications and timing of surgical and locoregional therapies for metastatic colorectal cancer, particularly in patients with liver-limited or oligometastatic disease.4.     Describe the multidisciplinary management of mCRC, including the roles of radiation therapy, systemic therapy sequencing, and palliative interventions to optimize outcomes and quality of life.References:Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S. & Kopetz, S. Advancements in combining targeted therapy and immunotherapy for colorectal cancer. Trends Cancer 10, 598–609 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38821852/Napolitano, S. et al. BRAFV600E mutant metastatic colorectal cancer: Current advances in personalized treatment and future perspectives. Cancer Treat. Rev. 134, (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40009904/Ciardiello, F. et al. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA. Cancer J. Clin. 72, 372–401 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35472088/Kim, S. Y. & Kim, T. W. Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer. ESMO Open 5, e000634 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/32188714/Biller, L. H. & Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 325, 669–685 (2021). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33591350/Smith, J. J. et al. Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusion. Cancer Med. 8, 6538–6548 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31503397/Saadat, L. V. et al. Hepatic Artery Infusion Chemotherapy Compared to Transarterial Radioembolization For Unresectable Colorectal Liver Metastases. Ann. Surg. 10.1097/SLA.0000000000006851 doi:10.1097/SLA.0000000000006851. PubMed Link: https://pubmed.ncbi.nlm.nih.gov/?term=10.1097/SLA.0000000000006851 (Linked via DOI search as the direct PMID is still indexing)Xiao, A. & Fakih, M. KRAS G12C Inhibitors in the Treatment of Metastatic Colorectal Cancer. Clin. Colorectal Cancer 23, 199–206 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38825433/André, T. et al. Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer. N. Engl. J. Med. 383, 2207–2218 (2020). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/33264544/Morris, V. K. et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline. J. Clin. Oncol. 41, 678–700 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/36252154/Xu, Z. et al. Treatments for Stage IV Colon Cancer and Overall Survival. J. Surg. Res. 242, 47–54 (2019). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/31071604/Smith, J. J. & D'Angelica, M. I. Surgical Management of Hepatic Metastases of Colorectal Cancer. Hematol. Oncol. Clin. North Am. 29, 61–84 (2015). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/25475573/Strickler, J. H. et al. Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study. Lancet Oncol. 24, 496–508 (2023). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/37142372/Kruijssen, D. E. W. van der et al. Upfront resection versus no resection of the primary tumor in patients with synchronous metastatic colorectal cancer: the randomized phase III CAIRO4 study conducted by the Dutch Colorectal Cancer Group and the Danish Colorectal Cancer Group. Ann. Oncol. 35, 769–779 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38852675/Hitchcock, K. E., Romesser, P. B. & Miller, E. D. Local Therapies in Advanced Colorectal Cancer. Hematol. Oncol. Clin. North Am. 36, 553–567 (2022). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/35562258/Hitchcock, K. E. et al. Alliance for clinical trials in Oncology (Alliance) trial A022101/NRG-GI009: a pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer: evaluating radiation, ablation, and surgery (ERASur). BMC Cancer 24, 201 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/38350888/Adam, R. et al. Liver transplantation plus chemotherapy versus chemotherapy alone in patients with permanently unresectable colorectal liver metastases (TransMet): results from a multicentre, open-label, prospective, randomised controlled trial. The Lancet 404, 1107–1118 (2024). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/39306468/Elez, E. et al. Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer. N. Engl. J. Med. 392, 2425–2437 (2025). PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40444708/***Fellowship Application Link: https://forms.gle/QSUrR2GWHDZ1MmWC6Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.  If you liked this episode, check out our recent episodes here: https://behindtheknife.org/listenBehind the Knife Premium:General Surgery Oral Board Review Course: https://behindtheknife.org/premium/general-surgery-oral-board-reviewTrauma Surgery Video Atlas: https://behindtheknife.org/premium/trauma-surgery-video-atlasDominate Surgery: A High-Yield Guide to Your Surgery Clerkship: https://behindtheknife.org/premium/dominate-surgery-a-high-yield-guide-to-your-surgery-clerkshipDominate Surgery for APPs: A High-Yield Guide to Your Surgery Rotation: https://behindtheknife.org/premium/dominate-surgery-for-apps-a-high-yield-guide-to-your-surgery-rotationVascular Surgery Oral Board Review Course: https://behindtheknife.org/premium/vascular-surgery-oral-board-audio-reviewColorectal Surgery Oral Board Review Course: https://behindtheknife.org/premium/colorectal-surgery-oral-board-audio-reviewSurgical Oncology Oral Board Review Course: https://behindtheknife.org/premium/surgical-oncology-oral-board-audio-reviewCardiothoracic Oral Board Review Course: https://behindtheknife.org/premium/cardiothoracic-surgery-oral-board-audio-reviewDownload our App:Apple App Store: https://apps.apple.com/us/app/behind-the-knife/id1672420049Android/Google Play: https://play.google.com/store/apps/details?id=com.btk.app&hl=en_US

Colorectal cancer is one of the few cancers that can often be prevented through screening, yet far too many people aren’t getting screened on time. In this episode of Medically Speaking, Dr. Eve Glazier welcomes back the show’s very first guest, award-winning journalist Katie Couric, for an ongoing conversation and call to action for Colorectal Cancer Awareness Month. Joined by Fola May, MD, PhD, UCLA gastroenterologist, and researcher, they discuss what’s changed in the conversation around colorectal cancer, why screening matters more than ever, the symptoms people should never ignore, and how to choose among today’s screening options. They also explore the barriers that keep people from follow-through — and why turning awareness into action can save lives. Find Dr. Glazier online at: https://www.uclahealth.org/medicallyspeakinghttps://www.instagram.com/uclahealthmedicallyspeakinghttps://www.tiktok.com/@uclamedicallyspeaking https://www.instagram.com/dreveglazierSee omnystudio.com/listener for privacy information.

#943: Join us as we sit down with Dr. Karan Rajan – doctor, health educator, & bestselling author of This Book May Save Your Life & This is Vital Information. Known across social media for debunking viral health trends, he's become one of the most trusted voices in gut & general health. In this episode, Dr. Karan Rajan breaks down the alarming rise of colorectal cancer, how gut health impacts hormonal conditions like endometriosis, the truth about fiber intake, what your GI tract is really trying to tell you, & debunks today's biggest viral health trends.   To Watch the Show click HERE   For Detailed Show Notes visit TSCPODCAST.COM   To connect with Dr. Karan Rajan click HERE   To connect with Lauryn Bosstick click HERE   To connect with Michael Bosstick click HERE   Read More on The Skinny Confidential HERE   Head to our ShopMy page HERE and LTK page HERE to find all of the products mentioned in each episode.   Get your burning questions featured on the show! Leave the Him & Her Show a voicemail at +1 (512) 537-7194.   Shop LOAM at https://go.shopmy.us/p-43749215 and use code SKINNY20 for 20% off!    This episode is sponsored by The Skinny Confidential The beauty tool that started it all, redesigned to evolve with you. Shop Ice Roller at https://bit.ly/IceRollerSilver today.   This episode is sponsored by Beekeepers Natural's Go to http://beekeepersnaturals.com/SKINNY or enter code SKINNY to get 20% off your order!   This episode is sponsored by The American Beverage Association Visit http://goodtoknowfacts.org for more information.   This episode is sponsored by ARMRA Go to http://armra.com/SKINNY or enter SKINNY to get 30% off your first subscription order.   This episode is sponsored by The RealReal Get $25 off your first purchase when you go to http://TheRealReal.com/skinny.   This episode is sponsored by Ollie Go to http://ollie.com/skinny and use code skinny to get 60% off your first box!   This episode is sponsored by Just Thrive Get your health in check and save 20% on your first order at https://justthrivehealth.com/SKINNY.   This episode is sponsored by Bobbie If you want to feed with confidence too, head to http://hibobbie.com to find the formula trusted by parents and loved by their babies—700k and counting. Produced by Dear Media

Colorectal cancer is rising quickly among young adults – in fact, it's the leading cause of cancer deaths for adults under 50 in the United States. And after actor James Van Der Beek's diagnosis and death at 48, many are wondering how to tell when everyday symptoms might actually be something more serious. On this week's Paging Dr. Gupta, we break down the red flags and tell you what to know about screening. Plus, vibration plates are popping up in gyms and living rooms — but do they actually deliver the benefits they promise?  More on what's behind the rise of colon cancer in young people with Dr. Kimmie Ng. This episode was produced by Andrea Kane, Jennifer Lai and Kyra Dahring.  Showrunner: Amanda Sealy  Senior Producer: Dan Bloom Technical Director: Dan Dzula Learn more about your ad choices. Visit podcastchoices.com/adchoices